Catch the knife !I found this stock interesting for in-day trading on Monday, Jan 24, if we will go green in SPX, it might go up to $4.00 at least. Also there is a big support right where the price seating now.
buy: $3.5-3.7
sell: 4.0-4.5
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.95 USD
−41.44 M USD
488.00 K USD
42.94 M
About Cardiff Oncology, Inc.
Sector
Industry
CEO
Mark Erlander
Website
Headquarters
San Diego
Founded
1999
FIGI
BBG000PXLKM7
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CRDF Daily chart Cup n handle formation. Waiting for a break above the cup for a buy . Pt 25 and sl 7
Cardiff Oncology Inc 🧙Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
If yo
$CRDF - Bullish$CRDF
Looking Bullish
In: 9.3 - 9.4
Target Price: 10.1
Stop Loss: 9:00
Risk rate: 2/1
CRDF Buy In Point is Here!CRDF is at a double support currently. Could be a really good buy in point here. Don't be afraid to buy in small portions. 1st target is $15 to see if we get past that natural resistance.
Options could be a possible way to go as well.
Also, don't forget Cardiff is speaking at a virtual presentati
Long | CRDF | Swing TradeNASDAQ:CRDF
Possible Scenario: LONG
Evidence: Price Action, Reversal Candlestick, Unusual option activities for Feb 19 at 20$
TP1: 15$, TP2: 19$
Mental Stop loss: 10.80$, risk reward ratio is 5 to 1
This is my idea and could be wrong 100%.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where CRDF is featured.
Frequently Asked Questions
The current price of CRDF is 3.08 USD — it has decreased by −24.69% in the past 24 hours. Watch Cardiff Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cardiff Oncology, Inc. stocks are traded under the ticker CRDF.
CRDF stock has fallen by −1.28% compared to the previous week, the month change is a 13.24% rise, over the last year Cardiff Oncology, Inc. has showed a 182.57% increase.
We've gathered analysts' opinions on Cardiff Oncology, Inc. future price: according to them, CRDF price has a max estimate of 13.00 USD and a min estimate of 7.00 USD. Watch CRDF chart and read a more detailed Cardiff Oncology, Inc. stock forecast: see what analysts think of Cardiff Oncology, Inc. and suggest that you do with its stocks.
CRDF reached its all-time high on Jun 10, 2005 with the price of 2,031.21 USD, and its all-time low was 0.70 USD and was reached on Mar 19, 2020. View more price dynamics on CRDF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CRDF stock is 48.42% volatile and has beta coefficient of 1.83. Track Cardiff Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cardiff Oncology, Inc. there?
Today Cardiff Oncology, Inc. has the market capitalization of 157.49 M, it has increased by 14.29% over the last week.
Yes, you can track Cardiff Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Cardiff Oncology, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
CRDF earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.27 USD resulting in a 7.22% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Cardiff Oncology, Inc. earnings.
Cardiff Oncology, Inc. revenue for the last quarter amounts to 165.00 K USD, despite the estimated figure of 70.00 K USD. In the next quarter, revenue is expected to reach 73.00 K USD.
CRDF net income for the last quarter is −11.86 M USD, while the quarter before that showed −11.78 M USD of net income which accounts for −0.65% change. Track more Cardiff Oncology, Inc. financial stats to get the full picture.
No, CRDF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 32.00 employees. See our rating of the largest employees — is Cardiff Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cardiff Oncology, Inc. EBITDA is −46.00 M USD, and current EBITDA margin is −9.22 K%. See more stats in Cardiff Oncology, Inc. financial statements.
Like other stocks, CRDF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cardiff Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cardiff Oncology, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cardiff Oncology, Inc. stock shows the neutral signal. See more of Cardiff Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.